<DOC>
	<DOC>NCT00076089</DOC>
	<brief_summary>The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Main FEV1/FVC ratio (postbronchodilator) ≤70% FEV1 (postbronchodilator) ≤50% of predicted Current smoker or exsmoker Clinically stable COPD indicated by no exacerbation and no change in COPD treatment of within 4 weeks prior to baseline Availability of chest xray dated a maximum of 6 months prior to study baseline or a willingness to have a chest xray performed at baseline Main COPD exacerbation indicated by a treatment with systemic glucocorticoids not stopped 4 weeks prior to baseline Lower respiratory tract infection not resolved 4 weeks prior to baseline Diagnosis of asthma and/or other relevant lung disease Known alpha1antitrypsin deficiency Need for longterm oxygen therapy defined as ≥16 hours/day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
</DOC>